At Agios, we put patient needs, concerns, input and collaboration at the center of our work. That’s how we help to ensure that the therapies we’re developing and the complementary support programs we’re providing address their needs and deliver the biggest impact possible.
Our ability to work together with patient communities, healthcare professionals, partners and colleagues – and honor each of their perspectives – powers our continued success in creating groundbreaking therapies for the patients who need them.
The intersection of our experiences and expertise catalyzes ideas and unearths insights. It sparks creativity. It creates efficiency. It drives scientific discoveries that result in pioneering therapies.
We are committed to continually raising the bar for ourselves and our science. But we don’t do it alone.
The relationships we cultivate across and outside of our organization deepen our impact as leaders in the field of cellular metabolism and propel our ability to bring new therapies to market.
What patients are
saying about us
living with sickle cell disease
Working with Agios has been a breath of fresh air! It is clear that the Agios team’s primary objective is to provide treatments that will address the needs of the patients they represent.
at the center
We’re here to make a difference in the lives of people with genetically defined diseases.
living with thalassemia
Patient engagement isn’t just a box-ticking exercise at Agios. They form sincere connections with patients and advocates, to be sure our perspective and experience are front and center from the start.
Our unmatched scientific expertise
For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together.
Our therapeutic areas of focus
We are discovering and developing therapies to treat genetically defined diseases. Building on our leadership in the field of cellular metabolism, we are advancing a robust late-stage pipeline of investigational medicines for the treatment of three distinct hemolytic anemias:
- Pyruvate Kinase (PK) Deficiency
- Sickle Cell Disease
At Agios, our culture is central to our success. And central to our culture is our commitment to maintaining a supportive and flexible work environment — where every person is encouraged to bring their whole selves to the office (physically or virtually).
We believe that when people feel seen and respected, they’re able to do their best work. Each of us bringing our best enables Agios to push the boundaries of science and make the biggest impact possible in the lives of people with genetically defined diseases.
Join our team
Do you want to be part of a team that knows how to turn great science into medicines that change lives? Explore our open positions!